Targets › SMARCA4
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.
ATPase involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. (UniProt, P51532)
Open in Phaseline: the race on SMARCA4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eli Lilly | LY4050784 SMARCA4/BRG1 inhibitor | SMARCA4 | Phase 1 | Metastatic Solid Tumor | Oct 2027 |
Metastatic Solid Tumor (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.